<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/DCD1B388-FA3D-4B30-8A06-5FB2BBF77BB7"><gtr:id>DCD1B388-FA3D-4B30-8A06-5FB2BBF77BB7</gtr:id><gtr:name>Pertinax Pharma Limited</gtr:name><gtr:address><gtr:line1>RED, SENATE HOUSE , TYNDALL AVENUE</gtr:line1><gtr:city>BRISTOL</gtr:city><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DCD1B388-FA3D-4B30-8A06-5FB2BBF77BB7" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>DCD1B388-FA3D-4B30-8A06-5FB2BBF77BB7</gtr:id><gtr:name>Pertinax Pharma Limited</gtr:name><gtr:address><gtr:line1>RED, SENATE HOUSE , TYNDALL AVENUE</gtr:line1><gtr:city>BRISTOL</gtr:city><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>489000.0</gtr:offerGrant><gtr:projectCost>489000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/406DEACE-7F4C-4E07-A830-84E2C53A6FB1"><gtr:id>406DEACE-7F4C-4E07-A830-84E2C53A6FB1</gtr:id><gtr:firstName>Michele</gtr:firstName><gtr:surname>Barbour</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=900030"><gtr:id>71F6B559-4E65-4FBB-9DEF-C503D5E951D1</gtr:id><gtr:title>ICURE Aid for Start Ups Cohort 3 - Pertinax Ltd</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Study</gtr:grantCategory><gtr:grantReference>900030</gtr:grantReference><gtr:abstractText>Pertinax is a novel formulation of the antimicrobial drug chlorhexidine (CHX) for use in dentistry and healthcare.

CHX is in widespread use but its efficacy and applications are limited by its short duration of activity, which is

typically less than 12 hours. This limitation is overcome by Pertinax technology, which extends the duration of

action to weeks, months or years. The company has confirmed market demand and has understood market size

and opportunity. The development of a robust and scaleable manufacturing process is now the principal barrier

to commercial success. The company believes that having established a manufacturing process it could a) supply

its technology in bulk form to customers to generate early income, b) complete one or more commercial

partnership deals currently in negotiation and c) raise commercial finance for development purposes.</gtr:abstractText><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>489000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">900030</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>